Drug Guidance for Subsidy 04/06/2025 Fruquintinib for previously treated metastatic colorectal cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended fruquintinib for inclus... See all × 04/06/2025 Fruquintinib for previously treated metastatic colorectal cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended fruquintinib for inclusion on the MOH List of Subsidised Drugs for treating patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF agent, and if RAS wild-type, an anti-EGFR agent. The decision was due to the unfavourable cost effectiveness of fruquintinib compared with subsidised alternative treatment, based on the price proposal from the company. Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 1 mg National Cancer Centre Capsule 5 mg National Cancer Centre
ORAL Select a brand starting with the letter: F FRUZAQLA CAPSULE 1MG [SIN17114P] FRUZAQLA CAPSULE 5MG [SIN17113P]